

EDWARDS LIFESCIENCES CORP  
Form 8-K  
December 05, 2006

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **November 29, 2006**

## EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**1-15525**  
(Commission  
file number)

**36-4316614**  
(IRS Employer  
Identification No.)

**One Edwards Way, Irvine, California**  
(Address of principal executive offices)

**92614**  
(Zip Code)

**(949) 250-2500**

Registrant's telephone number, including area code

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-Commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c)

---

**Item 2.05**            **Costs Associated with Exit or Disposal Activities.**

On November 29, 2006, an affiliate of Edwards Lifesciences Corporation (the Company) decided to discontinue its sales activity related to the Optiwave 980 Cardiac Laser Ablation System (Atrial Fibrillation Program). In addition, the Company is realigning resources to better drive key strategic opportunities. These combined changes result in the elimination of approximately 70 full-time positions, primarily in the U.S.

As a result of these actions, the Company expects to record a pre-tax charge in the fourth quarter 2006 of approximately \$16 million, of which approximately \$9 million will be non-cash. The charge consists of assets write-offs (intangibles, inventory and fixed assets) related to the Atrial Fibrillation Program in the amount of \$9 million, and employee severance and benefit costs in the amount of \$7 million.

Sales of the Optiwave 980 Cardiac Ablation System were less than \$1 million for the nine months ended September 30, 2006.

On December 5, 2006, the Company issued a press release announcing the above actions. A copy of the press release is attached as Exhibit 99.1.

**Item 2.06**            **Material Impairments.**

The information set forth under Item 2.05 (Costs Associated with Exit or Disposal Activities) is incorporated herein by reference.

**Item 9.01.**                            **Financial Statements and Exhibits.**

(d)            **Exhibits**

99.1            Press release, dated December 5, 2006, reporting the Company's decision to reorganize operations.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 5, 2006

**EDWARDS LIFESCIENCES CORPORATION**

By:                   /s/ Jay P. Wertheim  
                          Jay P. Wertheim  
                          Vice President,  
                          Associate General Counsel  
                          and Secretary

3

---

**Exhibit Index**

Exhibit Number	Description
99.1	Press release, dated December 5, 2006, reporting the Company's decision to reorganize operations.

4

---